Sino Medical Sciences Technology, Inc. (688108) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sino Medical Sciences Technology, Inc.

Why is Sino Medical Sciences Technology, Inc. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of 4.57% and Operating profit at -26.36% over the last 5 years

Positive results in Sep 25

OPERATING CASH FLOW(Y) Highest at CNY 165.49 MM
PRE-TAX PROFIT(Q) At CNY 10.51 MM has Grown at 4,105.29%
NET PROFIT(Q) At CNY 7.28 MM has Grown at 279.11%

With ROE of -0.06%, it has a risky valuation with a 12.36 Price to Book Value

Over the past year, while the stock has generated a return of 97.20%, its profits have risen by 95.5%

Market Beating performance in long term as well as near term

Along with generating 97.20% returns in the last 1 year, the stock has outperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Sino Medical Sciences Technology, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sino Medical Sciences Technology, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Sino Medical Sciences Technology, Inc.

84.08%

1.37

74.45%

China Shanghai Composite

21.43%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

14.80%

EBIT Growth (5y)

29.84%

EBIT to Interest (avg)

-61.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.15

Sales to Capital Employed (avg)

0.43

Tax Ratio

50.89%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.63

EV to EBIT

69.06

EV to EBITDA

36.54

EV to Capital Employed

7.19

EV to Sales

9.46

PEG Ratio

0.07

Dividend Yield

ROCE (Latest)

10.41%

ROE (Latest)

7.24%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

27What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 183.54 MM

NET SALES(HY)

At CNY 301.29 MM has Grown at 26.43%

ROCE(HY)

Highest at 7.39%

RAW MATERIAL COST(Y)

Fallen by -64.46% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -23.77 %

INVENTORY TURNOVER RATIO(HY)

Highest at 2.37 times

PRE-TAX PROFIT(Q)

At CNY 30.28 MM has Grown at 76.98%

NET PROFIT(Q)

At CNY 24.46 MM has Grown at 106.93%

-1What is not working for the Company

OPERATING PROFIT MARGIN(Q)

Lowest at 20.57 %

Here's what is working for Sino Medical Sciences Technology, Inc.

Operating Cash Flow

Highest at CNY 183.54 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

At CNY 301.29 MM has Grown at 26.43%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

At CNY 30.28 MM has Grown at 76.98%

over average net sales of the previous four periods of CNY 17.11 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 24.46 MM has Grown at 106.93%

over average net sales of the previous four periods of CNY 11.82 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Debt-Equity Ratio

Lowest at -23.77 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio

Highest at 2.37 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -64.46% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sino Medical Sciences Technology, Inc.

Operating Profit Margin

Lowest at 20.57 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales